REG - ReNeuron Group plc - Directorate Change

ReNeuronAnnouncement

17/04/2024 11:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240417:nRSQ9914Ka&default-theme=true

RNS Number : 9914K  ReNeuron Group plc  17 April 2024

17 April 2024

 

ReNeuron Group plc

("ReNeuron", the "Group" or the "Company")

 

Resignation of Chief Financial Officer

 

ReNeuron Group plc (in administration) (AIM: RENE), a UK based leader in stem
cell derived exosome technologies, announces that John Hawkins will be
stepping down as Chief Financial Officer ("CFO") of the Company with effect
from 7 May 2024, in order to pursue other opportunities. Notwithstanding his
departure, John will continue to provide support to the Company during the
ongoing administration process.

 

Iain Ross, Executive Chairman, said:

"The Board takes this opportunity to thank John for his valued contribution to
the Group during his tenure and wish him every success for the future."

 

Enquiries:

 

 Cork Gully LLP                     +44 (0)20 7268 2150 or
 Stephen Cork, Joint Administrator  reneuron@corkgully.com
 Mark Smith, Joint Administrator

 ReNeuron                           www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Executive Chairman      Via Walbrook PR

 Allenby Capital Limited (Nominated Adviser and Broker)                                +44 (0)20 3328 5656
 James Reeve/George Payne/ Dan Dearden-Williams (Corporate Finance)
 Stefano Aquilino/Kelly Gardiner (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)                    +44 (0)20 7933 8780 or reneuron@walbrookpr.com
                                                             (mailto:reneuron@walbrookpr.com)
 Paul McManus / Alice Woodings      +44 (0)7980 541 893 / +44 (0)7407 804 654

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABGGDSLBBDGSR